Mission appoints chief business officer
This article was originally published in Scrip
Executive Summary
Cambridge, UK-based Mission Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, has named Dr Paul Wallace chief business officer. Dr Wallace was most recently executive vice-president and head of business development at Medivir, where he was also a member of the executive management team responsible for strategic and operational leadership, R&D portfolio management and investment planning.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.